Anti-Spike RBD Antibody (Tixagevimab)
Catalog No.
F1031
Anti-Spike RBD Antibody (Tixagevimab)
Featured Products
Tixagevimab (AZD8895) is a humanized monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and S glycoprotein ectodomain and blocking S glycoprotein-mediated binding to the receptor.
146.48 kDa
Dry ice
2420564-02-7
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AZD 8895, AZD-8895, AZD8895
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Human
Unconjugated
Monoclonal
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Spike RBD
Please avoid freeze-thaw cycles.